Tánaiste announces multi-million Euro R&D support of ICON to accelerate decentralised clinical trial technology
The R&D support will help development of tech-enabled systems that provide greater flexibility and reduce the burden felt by clinical trial participants.
ICON plc to present at the Wells Fargo 16th Annual Healthcare Conference and the Baird Global Healthcare Conference
Thursday, September 9, 2021 at 8.00am ET
ICON reports second quarter 2021 financial results
Quarter 2 reported revenue of $871.2 million representing a year on year increase of 40.5% and 1.5% increase on Quarter 1 2021.
ICON acquisition creates world-leading healthcare intelligence and clinical research organisation
The combined company will leverage its enhanced operations to transform clinical trials and accelerate biopharma customer’s commercial success through the development of medicines and medical devices.
ICON shareholders vote in favour of all resolutions at its Extraordinary General Meeting
All resolutions at the ICON Extraordinary General Meeting held on June 15, 2021 (which resolutions had all been recommended by the Board) were all duly passed by shareholders.
ICON plc to Present at the Jefferies Virtual Healthcare Conference and the William Blair 41st Growth Stock Conference
The William Blair 41st Growth Stock Conference on Wednesday, June 2, 2021.
ICON plc to Present at the BofA Securities 2021 Virtual Healthcare Conference
The BofA Securities 2021 Virtual Healthcare Conference on Wednesday, May 12, 2021. The presentation will be webcast live from 08.00am ET.
ICON Reports First Quarter 2021 Results
Record net business wins in the quarter of $1,100 million, an increase of 27% year on year; a net book to bill of 1.28.
ICON wins multiple categories in 2021 CRO Leadership Awards for the fourth year in a row
ICON received 2021 CRO Leadership Awards. ICON achieved awards in both the Big Pharma and Overall groups.
Barclays Global Healthcare Conference
ICON plc to Present at the Barclays Global Healthcare Conference and the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum